NYSE:PHGE

Biomx Stock Insider Trading

Healthcare > Biotechnology

Buy PHGE

*Your capital is at risk

$0.87

-0.0224 (-2.52%)

At Close: Jun 03, 2026

BiomX Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 8.43. In total, the insiders bought 42.14M and sold 5.92M PHGE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	8.43
● Buy	42.14M shares
● Sell	5.92M shares
89% Buy Activity Weak Negative Correlation
Sell Signal Low Confidence Mar 17, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 16, 2024 Buy	Common Stock A-Award	Oron Assaf Chief Business Officer	Officer	25 804 Value: $483.0K
Sep 16, 2024 Buy	Common Stock A-Award	Solomon Jonathan Eitan Chief Executive Officer	CEO / President	50 556 Value: $946.3K
Sep 16, 2024 Buy	Common Stock A-Award	Bassan Merav Chief Development Officer	Officer	31 749 Value: $594.2K
Jul 15, 2024 Sell	Series X Preferred Stock C-Conversion	Cystic Fibrosis Foundation 10 Percent Owner	10% Owner	8 547 Value: $0
Jul 15, 2024 Sell	Series X Preferred Stock C-Conversion	Cystic Fibrosis Foundation 10 Percent Owner	10% Owner	8 547 Value: $0
Jul 15, 2024 Buy	Common Stock M-Exempt	Flynn James E *director By Deputization	Director	5 883 000 Value: $0.38B
Jul 15, 2024 Buy	Series X Non-Voting Convertible Preferred Stock M-Exempt	Flynn James E *director By Deputization	Director	5 883 Value: $380.0K
Jul 15, 2024 Buy	Series X Non-Voting Convertible Preferred Stock M-Exempt	Flynn James E *director By Deputization	Director	5 883 Value: $380.0K
Jul 15, 2024 Buy	Common Stock M-Exempt	Flynn James E *director By Deputization	Director	5 883 000 Value: $0.38B
Jul 11, 2024 Buy	Stock Option (Right to Buy) A-Award	Flynn James E *director By Deputization	Director	264 000 Value: $95.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Blum Susan Director	Director	264 000 Value: $95.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Greig Russell Director	Director	352 000 Value: $127.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Bassan Merav Chief Development Officer	Officer	950 000 Value: $344.9K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Wolfson Marina Chief Financial Officer	C-Suite Officer	950 000 Value: $344.9K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Solomon Jonathan Eitan Chief Executive Officer	CEO / President	3 805 000 Value: $1.38M
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Leff Jonathan S Director	Director	264 000 Value: $95.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Goodman Jesse Director	Director	264 000 Value: $95.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Merril Gregory Louis Director	Director	264 000 Value: $95.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Williams Eddie Director	Director	176 000 Value: $63.9K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Oron Assaf Chief Business Officer	Officer	237 500 Value: $86.2K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Moses Alan Charles Director	Director	176 000 Value: $63.9K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Wolfson Marina Chief Financial Officer	C-Suite Officer	950 000 Value: $344.9K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Bassan Merav Chief Development Officer	Officer	950 000 Value: $344.9K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Greig Russell Director	Director	352 000 Value: $127.8K
Jul 11, 2024 Buy	Common Stock Options - Right to Buy A-Award	Blum Susan Director	Director	264 000 Value: $95.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOMX INC.

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for ...

Read Full Profile Here